WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million
Key Highlights
- ➤ABVC closes private placement generating approximately $3.39 million gross proceeds
- ➤OID Notes carry 17.5% discount and $4.106 million aggregate principal
- ➤Notes mature June 30, 2027 and become convertible after eight months
- ➤ABVC will use proceeds for working capital, subsidiaries, and a $625,000 settlement
- ➤Conversion price equals 85% of three-day VWAP, subject to a floor price
WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million PR Newswire
JERSEY CITY, N.J., Nov. 2, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), has closed a private placement of original issue discount senior convertible promissory notes ("OID Notes") pursuant to a securities purchase agreement with institutional and other accredited investors, generating aggregate gross proceeds of approximately $3.39 million, before placement agent fees and other offering expenses.
Get started
Create a free account to read the full story.